Literature DB >> 23042635

PD-1 targeting in cancer immunotherapy.

Robert Ferris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23042635      PMCID： PMC3775858          DOI： 10.1002/cncr.27832

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  17 in total

1.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

Review 2.  Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing.

Authors:  S Radoja; A B Frey
Journal:  Mol Med       Date:  2000-06       Impact factor: 6.354

3.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 4.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

5.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

6.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Authors:  Kaori Sakuishi; Lionel Apetoh; Jenna M Sullivan; Bruce R Blazar; Vijay K Kuchroo; Ana C Anderson
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

7.  Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.

Authors:  Carolina Boni; Paola Fisicaro; Caterina Valdatta; Barbara Amadei; Paola Di Vincenzo; Tiziana Giuberti; Diletta Laccabue; Alessandro Zerbini; Albertina Cavalli; Gabriele Missale; Antonio Bertoletti; Carlo Ferrari
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

8.  Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

Authors:  Sabine Mumprecht; Christian Schürch; Juerg Schwaller; Max Solenthaler; Adrian F Ochsenbein
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

9.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

10.  Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.

Authors:  Lucy Golden-Mason; Brent Palmer; Jared Klarquist; John A Mengshol; Nicole Castelblanco; Hugo R Rosen
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103
View more
  11 in total

1.  Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model.

Authors:  Li-Li Guo; Gang-Cheng Wang; Peng-Jie Li; Cui-Mei Wang; Lin-Bo Liu
Journal:  Exp Ther Med       Date:  2018-04-23       Impact factor: 2.447

2.  Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.

Authors:  Fang Zheng; Jianzhong Dang; Hongyu Zhang; Fangzhou Xu; Diandian Ba; Bingyu Zhang; Fanjun Cheng; Alfred E Chang; Max S Wicha; Qiao Li
Journal:  J Immunother       Date:  2018-10       Impact factor: 4.456

3.  Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice.

Authors:  Ying-Ying Cheng; Bei-Yu Chen; Gan-Lan Bian; Yin-Xiu Ding; Liang-Wei Chen
Journal:  Mol Neurobiol       Date:  2022-02-10       Impact factor: 5.590

4.  PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Authors:  Benjamin A Kansy; Fernando Concha-Benavente; Raghvendra M Srivastava; Hyun-Bae Jie; Gulidanna Shayan; Yu Lei; Jessica Moskovitz; Jennifer Moy; Jing Li; Sven Brandau; Stephan Lang; Nicole C Schmitt; Gordon J Freeman; William E Gooding; David A Clump; Robert L Ferris
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

5.  Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.

Authors:  Omar A Ali; Sarah A Lewin; Glenn Dranoff; David J Mooney
Journal:  Cancer Immunol Res       Date:  2015-12-15       Impact factor: 11.151

6.  Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner.

Authors:  Christodoulos Filippis; Katharina Arens; Gaetan Aime Noubissi Nzeteu; Gabriele Reichmann; Zoe Waibler; Peter Crauwels; Ger van Zandbergen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

7.  Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.

Authors:  Takayuki Takeda; Mayumi Takeuchi; Masahiko Saitoh; Sorou Takeda
Journal:  Thorac Cancer       Date:  2018-08-20       Impact factor: 3.500

Review 8.  The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.

Authors:  Xinbing Sui; Junhong Ma; Weidong Han; Xian Wang; Yong Fang; Da Li; Hongming Pan; Li Zhang
Journal:  Oncotarget       Date:  2015-08-14

Review 9.  Inflammatory microenvironment in the initiation and progression of bladder cancer.

Authors:  Xinbing Sui; Liming Lei; Liuxi Chen; Tian Xie; Xue Li
Journal:  Oncotarget       Date:  2017-10-06

10.  PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients.

Authors:  Wei Wang; Ge Shen; Shikai Wu; Shiping Song; Yanli Ni; Zhuoyao Suo; Xiangying Meng; Dan Li; Lin Zhou; Rimin Hao; Yaowei Zhao; Li Bai; Lili Hou; Bing Liu; Guangxian Liu
Journal:  Oncotarget       Date:  2017-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.